ZymoGenetics’ rhThrombin Expected To Launch In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Company anticipates recombinant human product could take market share away from competing King biologic.
You may also be interested in...
ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration
FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.
ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration
FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.
ZymoGenetics Files Recombinant Human Thrombin BLA
Seattle-based biotech’s rhThrombin would compete with King’s bovine-derived product.